ArticleGlobal medical genetics2026
GPI: A pan-cancer biomarker integrating genetic alterations, immune infiltration, and therapeutic response prediction.
Article in Global medical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose-6-phosphate isomerase (GPI) is a key metabolic enzyme implicated in tumorigenesis, yet its pan-cancer role and clinical significance remain incompletely understood. This study aimed to systematically characterize GPI expression, genetic alterations, clinical relevance, and biological functions across cancers, and validate its pro-oncogenic effects.We employed bioinformatics tools (GEPIA2, SangerBox 3.0, cBioPortal, TIMER 2.0, etc.) to analyze GPI expression, genetic alterations, and clinical relevance across multiple cancer types. In vitro experiments were conducted to validate its pro-oncogenic effects in LGG cells.Bioinformatics analyses showed that GPI was upregulated in 29 cancers and downregulated in 3 cancers. High GPI expression was associated with advanced stage, metastasis and poor prognosis. Genetic alterations positively regulated GPI expression, which was linked to cancer stemness, RNA modification, metabolic pathways and tumor immune microenvironment, and could predict chemotherapy response. In vitro experiments confirmed that GPI overexpression promoted LGG cell proliferation, colony formation and invasion, while knockdown inhibited these phenotypes. The correlation between DNA repair and GPI expression is interconnected through metabolic and genetic instability pathways, requiring further investigation.GPI acts as a pan-cancer pro-oncogenic factor and a promising diagnostic, prognostic, and therapeutic biomarker. Further research on its molecular mechanisms, particularly with DNA repair, will inform novel cancer treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.